RxDoctor Payments Data

Morris Kliger, DO

Family Medicine · Lansdale, PANPI 1124080817

Payments from drug & device makers

$2,460in general payments, 2019–2025

Across 131 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$370
  • Pfizer$312
  • Merck$215
  • Johnson & Johnson$204
  • Akcea Therapeutics, Inc.$167
  • GSK$166
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,44199%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,460 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$98,801
Medicare patients
650
Services billed
1,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$126,703
JanuviaSitagliptin Phosphate73$62,850
EliquisApixaban57$57,843
JardianceEmpagliflozin38$43,245
MounjaroTirzepatide27$37,885
JanumetSitagliptin Phos/Metformin Hcl22$27,650
XareltoRivaroxaban16$18,423
ZenpepLipase/Protease/Amylase11$18,227
WegovySemaglutide12$16,950
TradjentaLinagliptin17$16,761
FarxigaDapagliflozin Propanediol18$11,856
Levothyroxine Sodium514$7,188
Rosuvastatin Calcium419$6,570
Atorvastatin Calcium616$6,086
SymbicortBudesonide/Formoterol Fumarate13$4,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$155$143,653106 claims
MerckJanuvia, Janumet$215$90,50095 claims
PfizerEliquis, Paxlovid$312$60,70270 claims
Boehringer IngelheimJardiance, Tradjenta$38$60,00755 claims
Lilly USA, LLCMounjaro$86$37,88527 claims
Johnson & JohnsonXarelto$204$18,42316 claims
AstraZenecaFarxiga, Symbicort$114$16,48531 claims
AbbVieSynthroid$370$2,94858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Lansdale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →